Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative oncology-focused biotechnology company advancing novel therapies for aggressive cancers. This page serves as the definitive source for official announcements, clinical trial updates, and strategic developments from the company.
Investors and researchers will find timely updates on key initiatives including brain-penetrant drug candidates targeting the PI3K/Akt/mTOR pathway, regulatory milestones, and partnership agreements. Our curated collection features press releases covering clinical progress, scientific presentations, and corporate announcements – all essential for understanding Kazia’s position in cancer therapeutics.
Content highlights include updates on glioblastoma research programs, ovarian cancer clinical trials, and licensing collaborations that drive the company’s pipeline. Bookmark this page to stay informed about Kazia’s contributions to precision medicine and oncology innovation through verified, up-to-date information.
Kazia Therapeutics reported successful completion of stage 1 of the EVT801 Phase 1 clinical trial in advanced cancer patients. The Safety Review Team confirmed meeting primary and secondary objectives, determining a recommended phase 2 dose at 400mg BID. EVT801 showed promising clinical activity, especially in patients with advanced ovarian cancer. The trial included 26 patients across six dosing cohorts, with EVT801 being well-tolerated. CEO Dr. John Friend emphasized the need for new therapies in high-grade serous ovarian cancer patients.
FAQ
What is the current stock price of Kazia Therapeuti (KZIA)?
What is the market cap of Kazia Therapeuti (KZIA)?
